Search - tctmd.com

Displaying 781 - 800 of 2210

Sort: Relevancy | Date

News Daily News

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Michael O'Riordan

June 22, 2017

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

News Industry News

4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum

June 16, 2017

News Industry News

Mitralign announces enrollment of first European subject in Transcatheter Tricuspid Repair Study enrolled in SCOUT II Study with Trialign™ System for Transcatheter Tricuspid Repair

June 16, 2017

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

News Conference News TVT 2017

Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms

Shelley Wood

June 15, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Industry News

4C Medical's Mitral Regurgitation Therapy to be Featured in 2017 TVT Innovation Forum

June 08, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Conference News EuroPCR 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

Michael O'Riordan

May 26, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

Advertisement

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum

Mitralign announces enrollment of first European subject in Transcatheter Tricuspid Repair Study enrolled in SCOUT II Study with Trialign™ System for Transcatheter Tricuspid Repair

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

4C Medical's Mitral Regurgitation Therapy to be Featured in 2017 TVT Innovation Forum

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

More Early Stroke With SAVR Than TAVR in SURTAVI

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content